Clinical Trial Update: The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sodium bicarbonate (Nephrotrans) for calcification propensity in kidney transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• Nephrotrans (sodium bicarbonate)

Snippet

Sponsor: Prim. Priv. Doz. Dr. Daniel Cejka | Conditions: Kidney Transplant; Complications | Phase 2 | Status: WITHDRAWN